Bone-Repair Drug Failed in Breast Cancer Study
Novartis AG (Basel, Switzerland) will withdraw its US
and European applications for approval of Zometa
(zoledronic acid) for the prevention of breast cancer
recurrence. The decision is based on the 5-year results
of the Adjuvant Zoledronic Acid to Reduce Recurrence
(AZURE) study, in which Zometa failed to improve
dise...